The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Special PMP Increase to Offset 95% of Price Cuts for 150 Products: FY2023 Revision
Japan has unveiled the details of a special add-on measure for the price maintenance premium (PMP) to be applied in next April’s “off-year” drug re-pricing. According to the plan, additional premiums will be granted to compensate for 95% of the…
To read the full story
Related Article
- Japan to Cut 310 Billion Yen in Drug Spending in FY2023 Off-Year Revision: Ministers
December 22, 2022
- Pharma Industry Mixed on Off-Year Drug Price Revision Plan for FY2023
December 19, 2022
- Chuikyo OKs FY2023 Price Revision Outline Specifying “0.625 Times” Product Coverage Threshold
December 19, 2022
- Ministers Agree on “4.375%” Product Coverage Line for 2023 “Off-Year” Drug Price Revision
December 16, 2022
- Off-Year Re-Pricing Expected to Cover 70% of Listed Products; Special Steps for Unprofitable Drugs, Patented Meds
December 16, 2022
REGULATORY
- Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
- Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
- Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules
December 26, 2025
- Japan Cabinet OKs Record Social Security Spending in FY2026 Budget, 105 Billion Yen in Drug Price Cuts
December 26, 2025
- MHLW Names 77 Active Ingredients for OTC-Like Drug Charges
December 26, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…